AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Moyamoya Disease

Recent research efforts aimed at curing Moyamoya Disease.

Last updated

Moyamoya Disease

Overview

Moyamoya disease is a rare, progressive disorder in which the ends of the internal carotid arteries and nearby major brain arteries become narrowed or blocked. In response, the brain develops a fragile web of tiny collateral vessels—the “puff of smoke” appearance that gave the disease its name on angiography. Reduced or unstable blood flow can cause transient ischemic attacks, ischemic stroke, brain hemorrhage, seizures, headaches, and cognitive difficulties. It affects both children and adults, with a female predominance in adult cohorts; prognosis varies substantially, but recurrent stroke and neurological disability are major risks without effective restoration of blood flow. AHA/ASA scientific statement (ahajournals.org)

There is currently no treatment that reverses the underlying artery-wall disease or eliminates inherited susceptibility. Standard care is expert evaluation of cerebral blood flow and stroke risk, management of relevant medical risks, and—when symptoms or impaired blood-flow reserve justify it—surgical revascularization. Direct bypass connects a scalp artery to a brain artery immediately; indirect procedures place vascularized tissue near the brain to stimulate new collateral growth over time. These operations reduce stroke risk but are not molecular cures. AHA/ASA scientific statement (ahajournals.org)

Scope of Recent Research (2020–present)

Research activity since 2020 has expanded from improving bypass surgery toward identifying the biological drivers of vessel narrowing, especially genetic susceptibility involving RNF213, abnormal endothelial-cell function, inflammation, and impaired angiogenesis—the formation of new blood vessels. The field is producing useful disease models, imaging biomarkers, and adjunctive therapies, but it remains far from a curative gene, RNA, cell, or drug therapy; current clinical studies mainly aim to prevent stroke, improve surgical results, or personalize the timing and type of revascularization. Management review (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Genetic and endothelial-targeted strategies. Recent work has strengthened the case that RNF213 is not merely a genetic marker but may influence how blood-vessel lining cells respond to stress. In a 2024 study using patient blood cells and engineered human endothelial cells, the common RNF213 p.R4810K variant was associated with impaired autophagy—the cell’s system for recycling damaged components—and poorer vessel-forming function after oxygen-glucose deprivation. Rapamycin and cilostazol restored aspects of autophagy in the laboratory model, identifying a possible drug-development direction rather than an established patient treatment. RNF213 and autophagy study (pubmed.ncbi.nlm.nih.gov)

Other preclinical studies link reduced RNF213 function to abnormal vessel growth and remodeling through pathways such as Hippo signaling. These findings support the idea that future treatment may need to normalize vascular repair rather than simply stimulate more angiogenesis, because moyamoya collateral vessels are often fragile and inefficient. No gene-replacement, gene-editing, or RNA therapy has entered clinical testing for moyamoya disease as of October 23, 2026. RNF213–Hippo pathway study Management review (pubmed.ncbi.nlm.nih.gov)

Patient-derived stem-cell and organoid platforms. Researchers are using induced pluripotent stem cells (iPSCs)—adult patient cells reset to an early developmental state—to create endothelial cells, vascular smooth-muscle cells, and three-dimensional vascular organoids that preserve elements of patient-specific biology. A 2021 team generated a non-integrating iPSC line from a patient carrying RNF213 p.R4810K, creating a renewable resource for mechanism studies and drug screening. More recent organoid and single-cell work has identified abnormal smooth-muscle-cell migration and candidate remodeling pathways, but these platforms are tools for discovering therapies, not transplantable cell cures. Patient-derived RNF213 iPSC line Organoid and single-cell study (pubmed.ncbi.nlm.nih.gov)

Small molecules and vascular protection. A 2026 cell-culture study found that ferulic acid reduced oxidative injury and improved migration and tube formation in mouse brain microvascular endothelial cells subjected to oxygen-glucose deprivation, apparently through the SIRT1/HIF-1α/VEGF-A pathway. This is an early mechanistic result in a laboratory model, not evidence that ferulic acid is safe or effective for people with moyamoya disease. Ferulic-acid endothelial study (pubmed.ncbi.nlm.nih.gov)

Adjunctive angiogenesis and ischemia-conditioning approaches. Remote ischemic conditioning (RIC), in which a blood-pressure cuff repeatedly and briefly restricts blood flow to a limb, is being tested as a noninvasive way to increase tolerance to brain ischemia and possibly support vascular repair. In adults, a small randomized study reported improved cerebral blood flow and less stenotic progression after one year of RIC, but its sample was small and the major cerebrovascular-event difference was not statistically significant. Adult RIC randomized study (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

In a single-center randomized pediatric trial from Xuanwu Hospital/Capital Medical University, 46 children aged 4–14 years without prior revascularization received twice-daily RIC or sham treatment for one year and were followed for three years. RIC had no severe treatment-related adverse events and was associated with fewer major adverse cerebrovascular events and higher patient-reported clinical improvement; however, cerebral hemodynamic measurements did not differ significantly after treatment. This investigator-initiated intervention was a pilot randomized study rather than a conventional drug-development phase trial. Pediatric RIC trial (pubmed.ncbi.nlm.nih.gov)

A related experimental surgical strategy combines multiple burr holes—small openings intended to encourage transdural collateral growth—with erythropoietin (EPO), a drug proposed to enhance angiogenesis. In an Ajou University randomized trial of 42 evaluable patients with acute steno-occlusive stroke and impaired perfusion, the EPO-plus-burr-hole group had more trans-hemispheric revascularization at six months than the burr-hole-only group (90.5% versus 57.1%) without more treatment-related complications. Because the population was broader than moyamoya disease alone, this result is encouraging but cannot yet establish EPO as a moyamoya treatment or cure. EPO plus multiple-burr-hole trial (pubmed.ncbi.nlm.nih.gov)

The ongoing BLOSSOM study, sponsored by Vanderbilt University Medical Center and collaborating with Johns Hopkins Hospital, is an NIH-funded, non-drug human research study rather than a phased therapeutic trial. It plans to enroll 100 adults with idiopathic moyamoya disease undergoing clinically indicated surgery and uses advanced MRI, carbon-dioxide cerebrovascular-reserve testing, neurological examinations, and cognitive testing before and after revascularization; no results had been posted in the registry record reviewed for this report. BLOSSOM trial record (clinicaltrials.gov)

Methodologies and Scientific Approaches

The major methodological shift is toward linking human genetics with functional vascular models. Investigators combine patient blood-derived iPSCs, differentiated endothelial and smooth-muscle cells, organoids, oxygen-glucose-deprivation experiments, and animal models to determine how RNF213 variants affect vessel survival, migration, autophagy, and pathological angiogenesis. These systems can support targeted drug screening, including comparison of genetically matched cells with and without a disease-associated variant. Patient-derived RNF213 iPSC line RNF213 and autophagy study RNF213–Hippo pathway study (pubmed.ncbi.nlm.nih.gov)

Clinical researchers increasingly use quantitative biomarkers rather than stroke counts alone: arterial-spin-labeling MRI for blood flow, angiography for collateral formation, cerebrovascular reserve testing during controlled carbon-dioxide exposure, and cognitive assessments. BLOSSOM is designed to integrate these physiological, metabolic, imaging, and clinical measures to predict which patients will benefit most from revascularization. BLOSSOM trial record NIH-funded biomarker program (clinicaltrials.gov)

Leading Institutions and Funding

Important recent contributors include Ajou University Medical Center in South Korea, which has led EPO-assisted revascularization and RNF213 endothelial research; Xuanwu Hospital and Capital Medical University in China, which have led RIC trials; Tongji Hospital/Huazhong University of Science and Technology in China, which generated patient-specific iPSC resources; and Zhengzhou University People’s Hospital, which conducted recent endothelial-protection studies. EPO plus multiple-burr-hole trial Pediatric RIC trial Patient-derived RNF213 iPSC line Ferulic-acid endothelial study (pubmed.ncbi.nlm.nih.gov)

In the United States, Vanderbilt University, Johns Hopkins Hospital, and Kennedy Krieger Institute are participating in an NIH-supported program led by Manus Donahue under grant R01NS133101, funded from May 1, 2024 through April 30, 2029. Patient-led infrastructure is also growing: the MoyaMoya Foundation’s Global Moyamoya Patient Registry, hosted with Sanford Research through the CoRDS Rare Disease Registry, reported 506 participants from 24 countries in September 2026. NIH-funded biomarker program Global Moyamoya Patient Registry (kennedykrieger.org)

Strengths, Limitations, and Challenges

The strongest recent progress is practical: better characterization of surgical response, promising noninvasive adjuncts such as RIC, and laboratory systems that make it possible to test mechanisms in patient-relevant vascular cells. RIC has shown favorable safety signals in small studies, and EPO-assisted multiple-burr-hole treatment has shown enhanced collateral formation in a selected acute steno-occlusive-stroke population. Pediatric RIC trial EPO plus multiple-burr-hole trial (pubmed.ncbi.nlm.nih.gov)

The limitations are substantial. Moyamoya is biologically heterogeneous, RNF213 variants confer susceptibility rather than explaining every case, and the available interventional studies are generally small, single-center, and focused on surrogate outcomes or stroke prevention rather than reversing arterial disease. Revascularization itself carries risks including postoperative ischemia, hemorrhage, hyperperfusion syndrome, and seizures; in one pilot trial, RIC reduced perioperative complications but did not significantly improve one-year clinical outcomes or recurrent-stroke rates after bypass. Management review RIC around bypass pilot study (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

A true cure is not close as of October 23, 2026: no therapy has yet been shown to halt or reverse the arterial pathology across the diverse causes of moyamoya disease. The most meaningful milestones to watch are replication of RIC and EPO-assisted revascularization in larger multicenter trials; validation of MRI and blood-flow biomarkers that can guide earlier, personalized surgery; and studies showing that a molecular intervention identified through RNF213 patient-cell and organoid models improves durable vessel structure and clinical outcomes in humans. Management review NIH-funded biomarker program (pubmed.ncbi.nlm.nih.gov)

References

Don't see your disease? Request a report